Mitochonic Acid 5 Improves Duchenne Muscular Dystrophy and Parkinson's Disease Model of Caenorhabditis elegans

Int J Mol Sci. 2022 Aug 24;23(17):9572. doi: 10.3390/ijms23179572.

Abstract

Mitochonic Acid 5 (MA-5) enhances mitochondrial ATP production, restores fibroblasts from mitochondrial disease patients and extends the lifespan of the disease model "Mitomouse". Additionally, MA-5 interacts with mitofilin and modulates the mitochondrial inner membrane organizing system (MINOS) in mammalian cultured cells. Here, we used the nematode Caenorhabditis elegans to investigate whether MA-5 improves the Duchenne muscular dystrophy (DMD) model. Firstly, we confirmed the efficient penetration of MA-5 in the mitochondria of C. elegans. MA-5 also alleviated symptoms such as movement decline, muscular tone, mitochondrial fragmentation and Ca2+ accumulation of the DMD model. To assess the effect of MA-5 on mitochondria perturbation, we employed a low concentration of rotenone with or without MA-5. MA-5 significantly suppressed rotenone-induced mitochondria reactive oxygen species (ROS) increase, mitochondrial network fragmentation and nuclear destruction in body wall muscles as well as endogenous ATP levels decline. In addition, MA-5 suppressed rotenone-induced degeneration of dopaminergic cephalic (CEP) neurons seen in the Parkinson's disease (PD) model. Furthermore, the application of MA-5 reduced mitochondrial swelling due to the immt-1 null mutation. These results indicate that MA-5 has broad mitochondrial homing and MINOS stabilizing activity in metazoans and may be a therapeutic agent for these by ameliorating mitochondrial dysfunction in DMD and PD.

Keywords: MA-5; Parkinson’s disease; mitochondrial calcium; mitochondrial fragmentation; muscular dystrophy; rotenone.

MeSH terms

  • Adenosine Triphosphate
  • Animals
  • Caenorhabditis elegans / genetics
  • Humans
  • Indoleacetic Acids
  • Mammals
  • Muscular Dystrophy, Duchenne* / drug therapy
  • Muscular Dystrophy, Duchenne* / genetics
  • Parkinson Disease* / drug therapy
  • Phenylbutyrates
  • Rotenone / pharmacology

Substances

  • 4-(2,4-difluorophenyl)-2-(1H-indol-3-yl)-4-oxobutanoic acid
  • Indoleacetic Acids
  • Phenylbutyrates
  • Rotenone
  • Adenosine Triphosphate